It is made available under a CC-BY-NC-ND 4.0 International license .

1	Epidemiological Analysis of Confirmed Mpox Cases in Burundi, July to September 2024
2	
3 4 5	Alexis Nizigiyimana <sup>1#</sup> , Francois Ndikumwenayo <sup>2</sup> , Martin Manirakiza <sup>2,3</sup> , Monique van Lettow <sup>4,5</sup> , Adrienne K. Chan <sup>5,6,7</sup> , Laurens Liesenborghs <sup>8</sup> , Placide Mbala-Kingebeni <sup>9,10</sup> , Anne W. Rimoin <sup>11</sup> , Isaac I. Bogoch <sup>12</sup> , Jason Kindachuk <sup>13,14#</sup>
6	
7 8	<sup>1</sup> Department of Management, Evaluation and Health Policy, School of Public Health, Université de Montréal, Montreal, QC, Canada
9	<sup>2</sup> University of Burundi, Bujumbura, Bujumbura, Burundi
10	<sup>3</sup> Burundi NCD Alliance, Bujumbura, Burundi
11	<sup>4</sup> Madiro, Toronto, Canada.
12	<sup>5</sup> Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada
13	<sup>6</sup> Infection Prevention and Control, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
14 15	<sup>7</sup> Division of Infectious Diseases, Department of Medicine, University of Toronto, Toronto, ON, Canada
16	<sup>8</sup> Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium
17 18	<sup>9</sup> Institut National de Recherche Biomédicale (INRB), Kinshasa, Democratic Republic of the Congo
19 20	<sup>10</sup> Service de Microbiologie, Département de Biologie Médicale, Cliniques Universitaires de Kinshasa, Université de Kinshasa
21 22	<sup>11</sup> Fielding School of Public Health, University of California Los Angeles, Los Angeles, CA, USA
23	<sup>12</sup> Department of Medicine, University of Toronto, Toronto, ON, Canada
24 25	<sup>13</sup> Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, MB, Canada
26	<sup>14</sup> Department of Internal Medicine, University of Manitoba, Winnipeg, MB, Canada
27	
28	
29	
30	
31	#Corresponding Authors: Alexis Nizigiyimana ( <u>alexis.nizigiyimana@madiro.org</u> ); Jason

32 Kindrachuk (Jason.Kindachuk@umanitoba.ca)

It is made available under a CC-BY-NC-ND 4.0 International license .

## 33 ABSTRACT

34 This study analyzes mpox cases in Burundi from July to September 2024, following the

introduction of Clade Ib. During this time, 25.4% of 607 samples tested positive via PCR.

36 Children under 15 comprised 55.2% of cases, with a higher proportion of female children testing

positive. Geographic analysis demonstrates case concentration in Bujumbura Mairie (59.1%).

38 These findings highlight the importance of age- and sex-specific interventions for outbreak

39 containment and the need for targeted public health strategies in Burundi.

40

### 41 INTRODUCTION

Mpox is a zoonotic viral infectious disease first identified in the Democratic Republic of the
Congo (DRC) in 1970 (1-3). Monkeypox virus (MPXV) historically circulated in the tropical
forest regions of Central and West Africa, where it is considered endemic (4, 5). The virus is

45 subclassified into two clades: clade I, formerly known as the Congo Basin (Central Africa) clade,

and clade II, formerly known as the West African clade. Clade II is further subdivided into two

47 subclades: IIa and IIb, with the latter responsible for the global epidemic in 2022 (6, 7).

Historically, zoonosis has been the primary driver of MPXV infections in humans with secondary
infections through human-to-human contact. However, Clade IIb MPXV infections during the
2022 global epidemic were linked primarily to sustained human-to-human transmission (8)
including within the men who have sex with men (MSM) community (9). The emergence of

52 Clade Ib MPXV in South Kivu, DRC, has demonstrated similar transmission characteristics that

have included linkage to sexual networks and sustained human-to-human transmission (10).

54 However, unlike Clade IIb infections, Clade Ib mpox cases have not been overrepresented among

55 males in South Kivu. Further, recent expansion of Clade Ib into North Kivu, DRC, has included

56 probable transmission through non-sexual or intimate contacts that have included children. While

57 there may be reporting biases complicating a more wholesome understanding of mpox

58 epidemiology, containment and mitigation strategies in this ongoing public health emergency

59 must consider these clade-specific demographic considerations for mpox acquisition.

60 The ongoing historic national outbreak in DRC has resulted in international expansion of Clade

61 Ib MPXV to multiple countries within the region including Kenya, Rwanda, Uganda, and

It is made available under a CC-BY-NC-ND 4.0 International license .

62 Burundi. This has resulted in the first declaration of a public health emergency of continental

63 security by the Africa CDC and the second declaration of a public health emergency of

64 international concern for mpox by the World Health Organization. Concerningly, mpox cases in

65 Burundi have demonstrated an increasing trajectory following Clade Ib introduction that has

66 included broad geographic expansion to many provinces. Here, we provide an analysis of

67 demographic and epidemiological considerations for mpox in Burundi using mpox case data

68 from July to September 2024.

69

## 70 **RESULTS**

We analyzed national mpox testing and demographic data acquired in Burundi from 03 July
2024 to 09 September 2024. During this period, 14 samples were tested in July, with 349 tested

in the month of August, and 244 for September up to 09 September 2024 for a total of 607

samples tested by PCR for MPXV (Table 1). Of these, men comprised 305 samples (50.2%) and

vomen comprised 302 samples (49.8%). For all samples, 154 samples (25.4%) tested positive,

<sup>76</sup> 448 samples (73.8%) tested negative, and 5 samples (0.8%) were indeterminate. Of the positive

samples, most positive tests were from men (80/154; 51.9%) with women comprising 48.1% of

positive cases (74/154). Negative samples were nearly evenly split between men (223/448;

79 49.8%) and women (225/448; 50.2%).

In analyzing age demographics, the median age of all individuals tested was 7 years (IQR: 2-18 years) (Table 2). For mpox-positive cases, the median age was 9.5 years (IQR: 3-25 years). For males, the median age of positive cases was 17.5 years (IQR: 4.8-28.5 years). In contrast, the median age of females who tested positive was 6 years (IQR: 2-20 years). The median age of males and females that tested negative were similar at 7 years (IQR: 2-17.5 years) and 6 years (IQR: 2-14 years), respectively.

86 In analyzing overall age demographics with mpox positivity, children <15 years comprised the

majority of all positive cases (85/154; 55.2%) (Table 3). This was followed by those aged 15-30

88 years (45/154; 29.2%) and lastly individuals 30+ years (24/154; 15.6%). When factoring in sex

and age with mpox positivity, there was a greater proportion of females (47/154; 30.5%) than

90 males (38/154; 24.7%) for children <15 years. Proportions were comparable between females

It is made available under a CC-BY-NC-ND 4.0 International license .

and males for those 15-30 years at 13.6% (21/154) and 15.6% (24/154), respectively. For those
aged 30+ years, there was a greater proportion of males (18/154; 11.7%) than females (6/154;
3.9%).

We also assessed the geographic distribution of positive cases in Burundi (Table 4). Mpox 94 95 positive cases were identified from 14 provinces in Burundi with the majority of positive cases identified in Bujumbura Mairie (91/154; 59.1%) followed by Bubanza, Bujumbura, and Kayanza 96 with 10 cases reported from each (6.5% of positive cases). Associations between geographic 97 regions and age distribution of cases were limited due to the high proportion of overall mpox 98 cases reported from Bujumbura Mairie and much lower proportions in any of the other provinces 99 100 reporting. We did analyze age demographics in Bujumbura Mairie as compared to the complete national data set. When focusing on Bujumbura Mairie, where 59.1% (91/154) of all mpox cases 101 102 were reported, children <15 years comprised 45% of cases (44/91), followed by those aged 15-30 years at 35.2% (32/91) and lastly those 30+ years with 16.5% of cases (15/91). When combining 103 104 positive case data from all other provinces (63 cases total), children <15 years comprised the highest proportion of all cases at 65.1% (41/63), followed by those aged 15-30 years at 20.6% 105

106 (13/63) and those 30+ years at 14.3% (9/63).

Hospitalization data for confirmed mpox cases was available up to 25 September 2024 for a total 107 of 254 cases with 247 requiring care for more than one day (Table 5). Of these, 45 currently 108 remain in hospital, including 20 females and 25 males. The median age of those hospitalized was 109 110 19 (IQR: 8-28) with females being younger than males at 16 years (IQR: 7-25) versus 22 (IQR: 8-32), respectively. The overall duration of hospital admission was 8 days (IQR: 6-12) with 111 females and males having very similar hospitalization durations at 8 days (IQR: 5-9.8) and 9 112 days (IOR: 6-12), respectively. In regard to comorbidities among those hospitalized, none were 113 114 noted for the majority of the patients including107 females and 124 males (231 cases total). 115 Among the hospitalized female cases, HIV positivity was noted among 6 patients, followed by hypertension (3 cases), asthma (2 cases), and diabetes (1 case). For the hospitalized male cases, 116 117 the most prominent comorbidities were hypertension (4 cases), asthma (3 cases), diabetes (3 cases), and HIV (1 case). 118

119

#### 120 **DISCUSSION**

It is made available under a CC-BY-NC-ND 4.0 International license .

121 From January 2023 to present, broad geographic expansion of Clade I MPXV in the DRC has

resulted in the largest mpox outbreak in recorded history among all endemic countries.

123 Concerningly, this national outbreak has included the expansion of MPXV to all provinces in

124 DRC as well as the emergence of a new virus subclade, Clade Ib, associated with sustained

human-to-human transmission (10). While first reported in South Kivu province, DRC, Clade Ib

126 has undergone rapid regional expansion that has included introduction to North Kivu, DRC (11),

127 as well as dissemination to neighbouring countries in East Africa, including Uganda, Rwanda,

128 Kenya, and most notably Burundi.

Here, we provide the first assessments of demographic, epidemiological, and hospitalization data 129 130 from suspected and confirmed mpox cases in Burundi from 03 July 2024 to 09 September 2024. During this period, 607 suspected mpox cases underwent PCR testing with an overall mpox 131 132 positivity rate of 25.4%. This report provides important insights into Clade Ib mpox cases. Our analysis of sex and mpox positivity did not demonstrate a strong indication of sex-specific 133 134 determinates with both a 0.5-1% difference between males and females when considering PCR positive or negative results only. However, sex-specific differences were present when 135 136 considering age, mpox positivity, and hospitalization. While the median ages of males and females were very similar among mpox negative cases (7 years and 6 years, respectively) there 137 138 was a large median age difference between males and females for mpox positive cases (17.5 years and 6 years, respectively), highlighting potential disparate sex-based epidemiologic risk 139 factors for infection. Further segregation of the data into age range groups showed that females 140 had a higher PCR positivity as compared to males for children <15 years whereas these trends 141 142 were reversed when considering those aged 30+ years. Males also had a slightly higher mpox positivity percentage when considering those aged 15-30 years; however, this difference was 143 lowest amongst the age groupings. When considering hospitalization, females with mpox tended 144 to be younger than males (16 years compared to 22 years); however, the durations of 145 hospitalization were very similar at 8 days and 9 days, respectively. No fatalities were noted 146 among these patients though there were individuals still hospitalized at the time of this reporting. 147 Thus, this early data suggests that female mpox patients requiring hospitalization tended to be 148 younger than their male counterparts, there were no obvious indications of differences in 149 outcome or severity. These data provide important considerations for mpox response and 150 151 containment efforts in Burundi. Notably, this early epidemiological data suggests that female

It is made available under a CC-BY-NC-ND 4.0 International license .

children may be at higher risk for infection acquisition than their male counterparts whereas 152 males >30 years appear to be at higher risk for infection than females. Whether these data are 153 154 reflective of certain activities or behaviours associated with greater risk of MPXV infection across sex and age groups needs to be addressed. An additional important consideration from this 155 data is that while mpox cases in Burundi were overrepresented among children <15 years, the 156 median age of hospitalization for both males and females was >15 years, unlike Clade Ia where 157 the highest morbidity and mortality have been among children historically. Considerations 158 should include assessment of potential reporting biases by sex and age as well as activities 159 among these groups that may be associated with higher infection risks (e.g. household 160 caregiving, contact with contaminated materials). It is also prudent to consider recent data for 161 Clade Ib infections from North Kivu which included probable non-sexual (intimate) contact-162 based transmission events within and outside of households, including children (11). Thus, 163 community engagement and messaging activities in Burundi should consider these early 164 associations between mpox positivity status, sex, and age. 165

166 Geographic associations with mpox cases were perhaps unsurprising as the majority of cases were identified in Bujumbura Mairie Province (59.1%), which includes the city of Bujumbura 167 alone. The remaining cases were split among 13 additional provinces in Burundi with cases 168 169 ranging from 1 to 10 reported per province. Mpox testing data did not include specific geographic residences for individuals. Thus, whether the overrepresentation of cases within 170 Bujumbura Mairie is indicative of local mpox transmission alone, includes non-residents 171 reporting in the province due to healthcare and testing availability, or a combination thereof 172 173 should be considered.

This report provides an early assessment of the demographic and epidemiological characteristics
of Clade Ib mpox cases in Burundi and provide important insights for ongoing outbreak
containment and mitigation strategies, including community engagement and messaging
activities.

178

## **179 ETHICS STATEMENT**

It is made available under a CC-BY-NC-ND 4.0 International license .

180	Data was i	provided by	v country-wide i	nnov surveillance	program. Permission	to use this data was
190	Data was	provided by	y country-white i	iipox suivemance	program. remission	to use this data was

181 granted by the Institutional Ethics Committee at the Faculty of Medicine, University of Burundi

- 182 (CIEB-FMCHUK no. 02/09/2024).
- 183

#### **184 DATA AVAILABILITY**

185 All data produced in the present study are available upon reasonable request to the authors.

186

## 187 FUNDING

188 Funding for the work presented was provided by the International Mpox Research Consortium

189 (IMReC) through funding from the Canadian Institutes of Health Research and International

**190** Development Research Centre (grant no. MRR-184813).

191

#### **192 CONFLICT OF INTEREST**

193 IIB consults to the Weapons Threat Reduction Program at Global Affairs Canada.

194

195

## **196 REFERENCES**

197 1. Breman JG, Kalisa R, Steniowski MV, Zanotto E, Gromyko AI, Arita I. Human

198 monkeypox, 1970-79. Bull World Health Organ. 1980;58(2):165-82.

- 199 2. Foster SO, Brink EW, Hutchins DL, Pifer JM, Lourie B, Moser CR, et al. Human
- 200 monkeypox. Bull World Health Organ. 1972;46(5):569-76.
- 201 3. Ladnyj ID, Ziegler P, Kima E. A human infection caused by monkeypox virus in
- 202 Basankusu Territory, Democratic Republic of the Congo. Bull World Health Organ.
- 203 1972;46(5):593-7.

It is made available under a CC-BY-NC-ND 4.0 International license .

204	4.	Van Dijck C, Hoff NA, Mbala-Kingebeni P, Low N, Cevik M, Rimoin AW, et al.
205	Emerg	ence of mpox in the post-smallpox era-a narrative review on mpox epidemiology. Clin
206	Microl	biol Infect. 2023;29(12):1487-92.
207	5.	Okwor T, Mbala PK, Evans DH, Kindrachuk J. A contemporary review of clade-specific
208	virolog	gical differences in monkeypox viruses. Clin Microbiol Infect. 2023;29(12):1502-7.
209	6.	Ulaeto D, Agafonov A, Burchfield J, Carter L, Happi C, Jakob R, et al. New
210	nomen	clature for mpox (monkeypox) and monkeypox virus clades. Lancet Infect Dis.
211	2023;2	23(3):273-5.
212	7.	Thornhill JP, Barkati S, Walmsley S, Rockstroh J, Antinori A, Harrison LB, et al.
213	Monke	eypox Virus Infection in Humans across 16 Countries - April-June 2022. N Engl J Med.
214	2022;3	887(8):679-91.
215	8.	WHO. 2022-23 Mpox (Monkeypox) Outbreak: Global Trends. 2023.
216	9.	Tarin-Vicente EJ, Alemany A, Agud-Dios M, Ubals M, Suner C, Anton A, et al. Clinical
217	presen	tation and virological assessment of confirmed human monkeypox virus cases in Spain: a
218	prospe	ctive observational cohort study. Lancet. 2022;400(10353):661-9.
219	10.	Vakaniaki EH, Kacita C, Kinganda-Lusamaki E, O'Toole A, Wawina-Bokalanga T,
220	Mukac	li-Bamuleka D, et al. Sustained human outbreak of a new MPXV clade I lineage in eastern
221	Demo	cratic Republic of the Congo. Nat Med. 2024.
222	11.	Mukadi-Bamuleka D K-LE, Mulopo-Mukanya N, Amuri-Aziza A, O'Toole A et al. First
223	import	ed Cases of MPXV Clade Ib in Goma, Democratic Republic of the Congo: Implications
224	for Glo	obal Surveillance and Transmission Dynamics. medRxiv. 2024.

225

# 226 TABLES

227 Table 1: Mpox test results in Burundi by sex.

	Negative	Indeterminate	Positive
Male	223 (49.8%)	2 (0.33%)	80 (13.2%)
Female	225 (50.2%)	3 (0.49%)	74 (12.2%)
Total	448 (73.8%)	5 (0.82%)	154 (25.4%)

228

It is made available under a CC-BY-NC-ND 4.0 International license .

# Table 2: Age demographics for individuals tested for mpox in Burundi.

Median Age (year		Median Age (years)	
	Mpox +ve	Mpox -ve	
Male	17.5 (IQR: 4.8-28.5)	7 (IQR: 2-17.5)	
Female	6 (IQR: 2-20)	6 (IQR: 2-14)	
Total	9.5 (IQR: 3-25)	6 (IQR: 2-15)	

230

## Table 3: Age demographics by sex for all individuals with confirmed mpox.

	All	Male	Female
<15 years	85 (55.2%)	38 (24.7%)	47 (30.5%)
15-30 years	45 (29.2%)	24 (15.6%)	21 (13.6%)
30+ years	24 (15.6%)	18 (11.7%)	6 (3.90%)

232

# 233 Table 4: Confirmed mpox cases by province.

Province	Cases Reported
Bubanza	10 (6.49%)
Bujumbura	10 (6.49%)
Bujumbura	91 (59.1%)
Mairie	
Bururi	2 (1.30%)
Cibitoke	1 (0.65%)
Gitega	5 (3.25%)
Karusi	3 (1.95%)
Kayanza	10 (6.49%)
Makamba	1 (0.65%)
Muramvya	5 (3.25%)
Muyinga	7 (4.55%)
Mwaro	1 (0.65%)

It is made available under a CC-BY-NC-ND 4.0 International license .

Rumonge	3 (1.95%)
Ruyigi	5 (3.25%)
Total	154

234

## Table 5: Hospitalization data in Burundi up to 25 September 2024.

	Total	Median Age	Duration of Care
	Hospitalizations	(years)	(days)
Male	132	22 (IQR: 8-32)	9 (IQR: 6-12)
Female	115	16 (IQR: 7-25)	8 (IQR: 5-9.8)
Total	247	19 (IQR: 8-28)	8 (IQR: 6-12)

236

237